
Sign up to save your podcasts
Or


Call Nigel Coffey a change agent, or call him a serial innovator. Everywhere Nigel takes on a new leadership challenge, he executes a program that adds tangible bottom-line value to his new organization. Starting with industry benchmarking, following with an audit of payments to suppliers to identify root cause issues and control weaknesses, and progressing through a systematic program of automation, Nigel has succeeded time and time again in moving each company to world-class procure-to-pay processes and technologies.
In his career Nigel has held senior business service, finance and transformation roles at Pfizer, PepsiCo, Shire Pharmaceuticals/Takeda and now Alnylam Pharmaceuticals. As the Head of Finance operations at this rapidly-growing biotech, he's helping optimize the processes to help this company produce leading-edge therapies based on the latest RNA interference science.
Hear Nigel and Danny Thompson, SVP of Market & Product Strategy at apexanalytix, as they discuss:
Featuring: The latest 2021 benchmarking results from apexanalytix’s P2PKey Practices Benchmarking survey. The newest P2P survey data and insights from top tier global companies.
Webinar slides: https://bit.ly/3dFttvn
Webinar video: https://www.apexanalytix.com/resources/webinars/one-leader-s-proven-formula-dramatically-improve-finance-and-gbs-operations
Speakers:
By apexanalytix5
11 ratings
Call Nigel Coffey a change agent, or call him a serial innovator. Everywhere Nigel takes on a new leadership challenge, he executes a program that adds tangible bottom-line value to his new organization. Starting with industry benchmarking, following with an audit of payments to suppliers to identify root cause issues and control weaknesses, and progressing through a systematic program of automation, Nigel has succeeded time and time again in moving each company to world-class procure-to-pay processes and technologies.
In his career Nigel has held senior business service, finance and transformation roles at Pfizer, PepsiCo, Shire Pharmaceuticals/Takeda and now Alnylam Pharmaceuticals. As the Head of Finance operations at this rapidly-growing biotech, he's helping optimize the processes to help this company produce leading-edge therapies based on the latest RNA interference science.
Hear Nigel and Danny Thompson, SVP of Market & Product Strategy at apexanalytix, as they discuss:
Featuring: The latest 2021 benchmarking results from apexanalytix’s P2PKey Practices Benchmarking survey. The newest P2P survey data and insights from top tier global companies.
Webinar slides: https://bit.ly/3dFttvn
Webinar video: https://www.apexanalytix.com/resources/webinars/one-leader-s-proven-formula-dramatically-improve-finance-and-gbs-operations
Speakers: